ANTI CYSTIT (tablets for dogs more than 10 kg)

Round, yellow-coated tablets.

1 g of the product contains active substances (mg):

- nitroxoline – 105,0;

- drotaverine hydrochloride – 85,0.

Excipients: field horsetail herb extract, valerian extract, nettle leaf extract, juniper extract, liquorice root extract, lingonberry leaf extract, chamomile extract, talc, albumin (egg white), calcium stearate, polyvinylpyrrolidone, glucose, microcrystalline cellulose, sorbitol, lactose.

- tablet weighing 120 mg (contains nitroxoline – 12,6 mg and drotaverine hydrochloride – 10,2 mg);

- tablet weighing 240 mg (contains nitroxoline – 25,2 mg and drotaverine hydrochloride – 20,4 mg).

The product ANTI CYSTIT belongs to combination antimicrobial veterinary medicinal products and possesses antimicrobial, anti-inflammatory, spasmolytic, diuretic, and saluretic action.

Nitroxoline is an 8-hydroxyquinoline derivative. Nitroxoline selectively inhibits the synthesis of bacterial DNA, forming complexes with metal-containing enzymes of the microbial cell and preventing their binding to a specific substrate. Nitroxoline has bacteriostatic, bactericidal, and fungicidal effects.

Nitroxoline is active against a wide spectrum of Gram-positive (Staphylococcus spp, Corynebacterium spp.) and Gram-negative (Escherichia coli, Salmonella spp, Ureaplasma urealyticum) microorganisms and certain fungi, such as Candida spp. and dermatophytes, which cause urinary tract infections. Following oral administration, nitroxoline is rapidly absorbed from the gastrointestinal tract (over 90%). The maximum plasma concentration is reached in 1,5–2 hours. It is excreted mainly by the kidneys in an unchanged form, which creates a high therapeutic concentration in the urine (up to 100 mcg/ml). The concentration in the urine often exceeds the therapeutic dose by 10–100 times, which allows for the effective suppression of the growth of Gram-positive and Gram-negative bacteria.

Drotaverine exerts a prolonged spasmolytic, myotropic, and vasodilatory effect, alleviating smooth muscle spasms of the urinary tract and vesical tenesmus. Drotaverine is a potent spasmolytic. Its mechanism of action is associated with the inhibition of the phosphodiesterase IV enzyme in smooth muscle cells. This leads to the accumulation of cAMP, relaxation of the muscle wall, and elimination of the spasm (myotropic action) without affecting the autonomic nervous system. Drotaverine is rapidly and completely absorbed from the gastrointestinal tract. Its bioavailability is approximately 65%. The maximum concentration of drotaverine in the blood is observed in 45–60 min. It is evenly distributed in tissues, penetrating into smooth musculature. It does not penetrate the blood-brain barrier. The metabolism of drotaverine occurs in the liver. Within 72 hours, it is practically eliminated from the body, approximately 30% in the urine, and 50% in the faeces. A large proportion is excreted in the form of metabolites; it is not detected in an unchanged form in the urine.

The complex of biologically active substances of medicinal plants (field horsetail, valerian, nettle, juniper, liquorice, lingonberry, chamomile), included in the composition of excipients, contains flavonoids, essential oils, tannins, vitamins, and mineral compounds. These components have moderate antiseptic, diuretic, spasmolytic, and anti-inflammatory properties, which complement the action of the main components of the product and facilitate the elimination of urinary calculi in urolithiasis.

ANTI CYSTIT tablets, by the degree of their effect on the body, are classified as low-hazard substances and, in recommended doses, do not possess local irritant and sensitising effects.

For the treatment of acute and chronic inflammatory and infectious diseases of the urinary tract (cystitis, pyelonephritis, urethritis) and urolithiasis in dogs, caused by microorganisms susceptible to nitroxoline.

The recommended therapeutic single dose is 2,5 mg of nitroxoline and 2,0 mg of drotaverine hydrochloride per 1 kg of the animal's body weight.

For oral administration. Tablets should be administered individually, either mixed with feed or placed directly on the back of the tongue for therapeutic purposes 3 times a day for 7-14 days, in the following doses:

Skipping a scheduled dose of the product should be avoided, as this may lead to a decrease in treatment efficacy.

The duration of the course of administration of the medicinal product, as well as changes in dosage, are determined by the veterinarian depending on the condition of the animal, the severity, and the course of the disease.

Do not use in cases of hypersensitivity to nitroxoline, drotaverine, or to any of the excipients.

Do not use in animals with signs of acute cardiac, renal, and hepatic failure.

Do not use upon detection of resistant strains of pathogens.

Do not use for prophylactic purposes.

Do not use in debilitated and emaciated animals.

Upon application of the product in accordance with the package leaflet, adverse events and complications are generally not observed. In an animal with hypersensitivity to the components of the product, the following adverse reactions are possible: hypersalivation, manifestations of skin reactions (pruritus, erythema, oedema), change in urine colour (due to the excretion of nitroxoline via the kidneys), nausea or digestive disorders: diarrhoea or constipation. Due to the presence of drotaverine, with a significant overdose, a decrease in blood pressure is possible, which manifests as lethargy or weakness of the animal.

The product must be used according to the package leaflet.

Recommended doses should be adhered to.

Skipping a scheduled dose of the product may lead to a decrease in treatment efficacy. In the event of a missed scheduled dose of the product, administration of the product must be resumed as soon as possible in the same dose and according to the same regimen.

The use of the veterinary medicinal product should be based on the identification and susceptibility testing of target pathogens to nitroxoline. If this is not possible, treatment should be based on epizootiological information concerning the susceptibility of target pathogens at the local/regional level.

Due to the presence of lactose and glucose in the product, in cases of hyperglycaemia, diabetes mellitus, and allergy to dairy products in animals, the use of the product is possible only following consultation with a veterinarian.

The safety of the product for pregnant and lactating animals has not been established. The use of the product is permitted only in cases where the expected benefit to the mother significantly outweighs the potential risk to the foetus or neonates. The decision on administration is made by a veterinarian following an assessment of the animal's condition.

Synergism (enhancement of the effect) is observed when combining nitroxoline with tetracyclines, nitrofurans, and nalidixic acid.

Products containing magnesium, aluminium, or calcium may reduce the absorption of nitroxoline in the gastrointestinal tract (forming inactive complexes). It is recommended to maintain a 2-hour interval between administrations.

Upon simultaneous use with other spasmolytics (for example, atropine), an enhancement of the relaxing effect on the smooth musculature of the urinary tract is observed.

Simultaneous use with activated charcoal or other sorbents reduces the concentration of active substances in the blood.

When handling the product, general rules of personal hygiene and rules for handling veterinary products must be observed.

Tablets, weighing 120 and 240 mg in blister packs of 10 pieces, blisters of 1, 2, 3 or 5 pieces in a package. Polymer containers of 20, 30 or 50 tablets. Secondary packaging - cardboard box.

The product should be stored in the manufacturer's packaging, separately from food products and feed, in a dry place, protected from light and moisture, out of the reach of children, at a temperature from 5 to 25 °C.

3 years.